Novel treatment for PXE: Recombinant ENPP1 enzyme therapy
Molecular Therapy · 2024
DOI: 10.1016/j.ymthe.2024.09.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Ida Joely Jacobs und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Jefferson Institute of Molecular Medicine, Thomas Jefferson Universi…. Hauptthemen laut MEDLINE: Pyrophosphatases, Phosphoric Diester Hydrolases, Pseudoxanthoma Elasticum, ATP-Binding Cassette, Sub-Family C Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Pseudoxanthoma elasticum (PXE) is a genetic multisystem ectopic calcification disorder caused by inactivating mutations in the ABCC6 gene encoding ABCC6, a hepatic efflux transporter. ABCC6-mediated ATP secretion by the liver is the main source of a potent endogenous calcification inhibitor, plasma inorganic pyrophosphate (PPi); the deficiency of plasma PPi underpins PXE. Recent studies demonstrated that INZ-701, a recombinant human ENPP1 that generates PPi and is now in clinical trials, restored plasma PPi levels and prevented ectopic calcification in the muzzle skin of Abcc6-/-mice. This study examined the pharmacokinetics, pharmacodynamics, and potency of a new ENPP1-Fc isoform, BL-1118, in Abcc6-/- mice. When Abcc6-/- mice received a single subcutaneous injection of BL-1118 at 0.25, 0.5, or 1 mg/kg, they had dose-dependent elevations in plasma ENPP1 enzyme activity and PPi levels, with an enzyme half-life of approximately 100 h. When Abcc6-/- mice were injected weekly from 5 to 15 weeks of age, BL-1118 dose-dependently increased steady-state plasma ENPP1 activity and PPi levels and significantly reduced ectopic calcification in the muzzle skin and kidneys. These results suggest that BL-1118 is a promising second generation enzyme therapy for PXE, the first generation of which is currently in clinical testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, USA; PXE International Center of Excellence in R…
- Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Jacobs, I. J., Obiri-Yeboah, D., Stabach, P. R., Braddock, D. T., & Li, Q. (2024). Novel treatment for PXE: Recombinant ENPP1 enzyme therapy. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.09.028
Vancouver
Jacobs IJ, Obiri-Yeboah D, Stabach PR, Braddock DT, Li Q. Novel treatment for PXE: Recombinant ENPP1 enzyme therapy. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.09.028
BibTeX
@article{Jacobs2024,
author = {Jacobs, Ida Joely and Obiri-Yeboah, Dora and Stabach, Paul R and Braddock, Demetrios T and Li, Qiaoli},
title = {Novel treatment for PXE: Recombinant ENPP1 enzyme therapy},
journal = {Molecular Therapy},
year = {2024},
doi = {10.1016/j.ymthe.2024.09.028}
}
EUVIMED